Imetelstat was approved by the United States Food and Drug Administration in June 2024 and the European Medicines Agency in March 2025 for the treatment of certain patients with lower-risk …
Updated NCCN Guidelines Recommend Imetelstat to Treat Anemia …
Imetelstat is an liquidated oligonucleotide telomerase inhibitor approved for treating adult patients with low-to-intermediate-1 risk MDS with transfusion-dependent anemia.1 The first-in-class …
Updated NCCN Guidelines Recommend Imetelstat for Anemia …
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to recommend imetelstat (Rytelo) as a Category 1 and 2A treatment …
Why RYTELO (imetelstat) | RYTELOHCP
RYTELO® (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more …
Imetelstat (Rytelo): a promising treatment for adults with …
These molecular discoveries underscore Imetelstat’s capacity to impact the course of MDS, setting it apart from other treatments that chiefly target anemia-related symptoms. When …
FDA approves imetelstat for low- to intermediate-1 risk …
Drug Approvals and Databases Resources for Information | Approved Drugs FDA approves imetelstat for low- to intermediate-1 risk myelodysplastic syndromes with transfusion …
Institute for Clinical and Economic Review Publishes …
ICER posted its revised Evidence Report assessing the comparative clinical effectiveness and value of imetelstat (Rytelo, Geron Corporation) for the treatment of anemia in myelodysplastic …
Imetelstat: a new addition to the therapeutic landscape of …
Anemia is the most prevalent cytopenia in lower-risk myelodysplastic neoplasms (LR-MDS). There is a paucity of drugs for red blood cell transfusion dependence (RBC-TD), and …
Evaluating Imetelstat's Impact on Health-Related Quality of …
3 天之前 · The phase 3 IMerge trial (NCT02598661) evaluated how treatment with imetelstat impacts health-related quality of life in patients with lower-risk myelodysplastic syndromes …
Updated NCCN Guidelines Recommend Imetelstat for Symptomatic Anemia …
On July 26, Geron Corporation announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the …
- 某些结果已被删除